{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"The duration of time from study entry to time of death or the date of last contact.","groups":[{"description":"Gemcitabine 900 mg/m2 IV days 1 and 8 Docetaxel 75 mg/m2 IV day 8 GCSF 5 micrograms/kg days 9-15 or pegfilgrastim 6 mg day 9 or 10 Every 21 days for 4 cycles CT/MRI imaging to confirm disease-free Doxorubicin 60 mg/m2 IV every 21 days for 4 cycles","id":"OG000","title":"Regimen 1"},{"description":"Observation","id":"OG001","title":"Regimen II"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable participants","reportingStatus":"POSTED","timeFrame":"Follow-up every 4 months for 3 years, then every 6 months for 2 years.","title":"Number of Participants Who Experienced Death","type":"PRIMARY","unitOfMeasure":"Participants"}